相关临床试验
10
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
20.0%
已完成
5
50.0%
招募中
1
10.0%
撤回
2
20.0%
暂无批准数据
- CorMedix announced completion of enrollment in the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for preventing fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. - The study compares once-weekly rezafungin dosing versus standard antimicrobial regimens, with the primary endpoint of fungal-free survival at day 90 and topline results expected in Q2 2026. - REZZAYO represents a significant market opportunity with an estimated 130,000 patients constituting the addressable market for antifungal prophylaxis in the U.S. and a total addressable market exceeding $2 billion. - The drug currently has orphan drug exclusivity through 2035 and patent coverage through 2038, positioning CorMedix for potential FDA approval in this high-risk patient population with critical unmet medical needs.
- Faron Pharmaceuticals has appointed Ralph Hughes as Chief Business Officer, bringing extensive experience in commercial strategy and market access from his previous roles at PharmaVentures, Mundipharma, and Pfizer. - Hughes joins Faron at a critical time as the company advances its lead immunotherapy candidate bexmarilimab, currently in Phase I/II trials for acute myeloid leukemia and myelodysplastic syndrome. - Bexmarilimab targets the Clever-1 receptor on macrophages, potentially overcoming cancer treatment resistance by reprogramming the tumor microenvironment and enhancing immune system response against cancer cells.
- Prestige Biopharma has entered an exclusive commercialization agreement with Teva Israel for its trastuzumab biosimilar Tuznue (HD201) targeting HER2-positive breast cancer and gastric adenocarcinoma. - Phase 3 TROIKA trial data demonstrated equivalent efficacy to Herceptin with 46.6% complete response rate in the biosimilar arm versus 46.2% for the reference product. - The European Medicines Agency is currently reviewing the marketing authorization application for Tuznue based on positive clinical trial results. - This partnership expands Prestige's global commercialization strategy, following previous agreements with Pharmapark for Russia and Mundipharma for multiple European markets.
• Celltrion has received European regulatory approval to market its rituximab biosimilar under four different brand names - Truxima, Tuxella, Ritemvia, and Blitzima - in a unique market strategy. • The company's approach aims to maximize market share through potential partnerships with multiple distributors, building on their successful dual-brand strategy with their infliximab biosimilar. • Strategic differences in marketing authorizations include specific indications, with Ritemvia approved for chronic lymphocytic leukemia while Blitzima and Tuxella exclude this indication.
